Join to View Full Profile
101 Manning DrChapel Hill, NC 27514
Dr. Somasundaram is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Southwestern Medical SchoolClass of 2013
Certifications & Licensure
NC State Medical License 2021 - 2030
PA State Medical License 2018 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Start of enrollment: 2019 Jun 12
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Dysfunctional CD11cCD21extrafollicular memory B cells are enriched in the periphery and tumors of patients with cancer.Ayana T Ruffin, Allison N Casey, Sheryl R Kunning, Ian P MacFawn, Zhentao Liu
Science Translational Medicine. 2025-02-19 - Feasibility trial of STRONG: A digital intervention to improve nutritional management for individuals with esophageal and gastroesophageal junction cancer.Yu Chen Lin, Jose M Pimiento, Jeanine Milano, Diane Riccardi, Nakesha Mckinnie
Contemporary Clinical Trials Communications. 2025-02-01 - Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.Dylan Fortman, Hong Wang, Robert VanderWeele, Terry Evans, James G Herman
Clinical Lung Cancer. 2025-01-01
Press Mentions
Dysfunctional B Cells: New Cancer Immunotherapy TargetFebruary 20th, 2025- Scientists Identify a New Cancer Immunotherapy Target: Dysfunctional B CellsFebruary 19th, 2025
- Rashid Awarded Grant to Develop AI Tool That Recommends Optimal Clinical Trials to Pancreatic Cancer PatientsSeptember 24th, 2024
Grant Support
- The role of IL6-induced LAG3 as a resistance mechanism to PD1 blockade in NSCLC patientsUNIV OF NORTH CAROLINA CHAPEL HILL2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
